Sept. 17, 2007 - MicroIslet, Inc. (OTCBB:MIIS), a development-stage biotechnology company with patented and proprietary technologies focused on transplantation therapy for people with insulin-dependent diabetes, and Progenitor Cell Therapy, LLC (PCT), a leading cell therapy services company, announced today that they have signed an agreement for the manufacturing of MicroIslet's premier product, MicroIslet-P(tm), an Encapsulated Islet Cell Product for the Treatment of Type 1 Diabetes... Press release -
